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Creatine transport has been assigned to creatine transporter 1 (CRT1), encoded by mental retardation asso-
ciatedSLC6A8. Here, we identified a second creatine transporter (CRT2) known as monocarboxylate transporter
12 (MCT12), encoded by the cataract and glucosuria associated geneSLC16A12.A non-synonymous alteration
in MCT12 (p.G407S) found in a patient with age-related cataract (ARC) leads to a significant reduction of creatine
transport. Furthermore, Slc16a12 knockout (KO) rats have elevated creatine levels in urine. Transport activity
and expression characteristics of the two creatine transporters are distinct. CRT2 (MCT12)-mediated uptake
of creatine was not sensitive to sodium and chloride ions or creatine biosynthesis precursors, breakdown pro-
duct creatinine or creatine phosphate. Increasing pH correlated with increased creatine uptake. Michaelis–
Menten kinetics yielded a Vmax of 838.8 pmol/h/oocyte and a Km of 567.4 mM. Relative expression in various
human tissues supports the distinct mutation-associated phenotypes of the two transporters.SLC6A8was pre-
dominantly found in brain, heart and muscle, while SLC16A12 was more abundant in kidney and retina. In the
lens, the two transcripts were found at comparable levels. We discuss the distinct, but possibly synergistic func-
tions of the two creatine transporters. Our findings infer potential preventive power of creatine supplementation
against the most prominent age-related vision impaired condition.
INTRODUCTION
Creatine is an essential component of the cellular energy house-
hold. It can either be synthesized by the body using the amino
acids arginine, glycine and methionine or it can be supplied by
nutrition. Creatine is transported to target cells via the blood-
stream (1). After uptake into the cells, the phosphorylated
form aids in immediate supply of ATP, especially under high
demand of energy over a short period of time (2,3). Transport
of creatine across the membrane requires the creatine transpor-
ter1, CRT1, which is encoded by SLC6A8 located on the
X chromosome (OMIN 300036). CRT1 consists of twelve trans-
membrane domains (4,5). Creatine uptake is saturable and
requires sodium and chloride ions, enabling creatine transport
against its concentration gradient (5,6). SLC6A8 is most abun-
dant in tissues with high energy demand including skeletal
muscle, heart, brain and retina, but also in the intestine and
kidney epithelial cells (7–9). In this context, it is interesting to
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note that mutations in SLC6A8 primarily lead to mental retard-
ation in male patients (OMIM 300352) (10–12), while
kidney-related clinical features or those affecting vision have
not been reported.
The fourteen members of the monocarboxylate transporter
(MCT) family, encoded by the SLC16 genes also contain 12
transmembrane domains (13). They display distinct expression
patterns (14,15) and half of the MCT transporters, including
MCT12 encoded by SLC16A12 (OMIM 611910), are considered
orphans (16). Substrates for the other half are diverse molecules in-
cluding monocarboxylates, such as lactate, pyruvate and butyrate
(MCT1, 2, 3 and 4) (17), thyroid hormones (MCT8) (18) or aroma-
tic aminoacids (MCT10/TAT1) (19,20).The localizationof MCTs
to the plasma membrane requires distinct accessory proteins, such
as gp70/embigin for MCT2 or CD147/basigin for MCT1, 3, 4 and
MCT12 (21–24). Basedon the mutation analysis, the orphan trans-
porter MCT12 is likely to play a role in energy metabolism, since a
premature termination codon in the gene SLC16A12 causes catar-
acts of the human lens and glucosuria with elevated, non-diabetic
glucose levels in urine (OMIM 612018) (25,26). These findings
suggest MCT12-mediated reduced reabsorption of glucose in the
proximal convoluted tubules in kidney. Likewise, disturbed
energy homeostasis within the avascular crystalline lens may
result in opacities that cause cataracts. To be able to test this
hypothesis, knowledge of the identity of the substrate is essential.
To identify the substrate of MCT12, we combined the traditional
heterologous Xenopus laevis oocyte expression system with a
state-of-the-art metabolomics approach. Two possible candidates
were experimentally tested and one of them, creatine, could be
verified and characterized as a substrate for MCT12. This work
demonstrates the existence of a second creatine transporter with
distinct transport characteristics and expression patterns.
RESULTS
Injection of SLC16A12 cRNA leads to localization of
MCT12 at the Xenopus laevis oocyte membrane
Xenopus laevis oocytes were chosen as the experimental system
to investigate transport activity of MCT12. We either injected
human reference or human mutant SLC16A12 complementary
RNA (cRNA). The presence or absence of coinjected chaperone
CD147 cRNA was also tested because the chaperone CD147 was
shown to be necessary for proper localization of MCT12 in
HEK293 cells. Injection of CD147 cRNA alone served as a
control. Under all conditions when the transporter was injected,
a positive signal in the cell membrane was detected with
MCT12-specific antibodies. These results were independent of
the presence of the chaperone, suggesting that endogenous
Xenopus CD147 homologue levels seem to be sufficient for
MCT12 trafficking to the membrane. Oocytes injected with
only the chaperone CD147 cRNA did not yield a signal. As
expected, noninjected oocytes also did not show a positive
signal (Fig. 1). Specificity of the transporter signal was demon-
strated by the use of the secondary antibody alone (Supplemen-
tary Material, Fig. S1A). The membrane marker isolectin
B4 (IB4) was used to visualize the membranes in oocytes
(Supplementary Material, Fig. S1B). Taken together, we con-
cluded that the Xenopus laevis oocyte expression system
provides the experimental requirements necessary to apply a
metabolomics analysis in search for the MCT12 substrate.
Metabolomics approach suggested substrate candidates
A metabolomics approach was designed to narrow down the
number of potential substrate candidates. Cell extracts obtained
from oocytes that were either injected withCD147only (control)
or coinjected withCD147 and SLC16A12 cRNA were subjected
to the analysis of polar metabolites with liquid chromatography
and mass spectrometry (LC-MS), which yielded 14′720 m/z
values (ratio of ion mass (m) and its charge (z)). To exclude ana-
lytical and chemical noise, analysis was focused on m/z values
corresponding to the known biological metabolites by applica-
tion of a filter with the metabolites listed in the KEGG database
(Kyoto Encyclopedia, www.genome.jp/kegg/, last accessed on
15 April 2013). This resulted in 553 metabolite hits. The
observed intensity values of these metabolites were subjected
to between-group-analysis (BGA), contrasting samples of
injected oocyte lysates. This resulted in further reduction to 20
metabolites (Table 1). To evaluate these candidates, we consid-
ered the maximum fold change (log2 ratio) as well as statistical
significance (two-way ANOVA). The two candidates, creatine
(log2 ratio ¼ 22.6485 and P ¼ 3.11 × 1027) and L-glutamine
(log2 ratio¼ 0.9945 and P ¼ 0.0002), displayed statistically
highest significance. Furthermore, these candidates also belonged
to the group of monocarboxylates and matched the physiological
expectations of energy-related metabolites. Creatine yielded the
most significant difference between oocytes injected with
CD147 cRNA alone and those coinjected with CD147 and
Figure 1. Immunofluorescence images. Membrane localization of human
MCT12 (hMCT12) in Xenopus laevis oocytes injected with SLC16A12 cRNA.
Noninjected oocytes and those injected with the chaperone CD147 alone served
as controls (top row). Membrane localized signals (arrow) were detected only in
oocytes injected with MCT12, irrespective of the presence of chaperone CD147.
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SLC16A12 cRNA. The log2 ratio of 22.6485 corresponds to a
6.3-fold reduction in creatine levels (P, 0.0001, unpaired
t-test) (Fig. 2A), suggesting efflux of creatine.
Efflux and uptake of creatine by MCT12
To test whether creatine was indeed specifically transported by
MCT12, efflux experiments were performed, as suggested by
the metabolomics study. The time course (0, 15 and 60 min)
showed a significant increase in radioactivity (disintegrations
per minute, DPM) (P , 0.0001, ANOVA) in the medium
when oocytes were coinjected with the chaperone and
SLC16A12 cRNA (32+ 3, 1805+ 262, 6869+ 636 DPM for
the three time points, n ¼ 9), verifying creatine efflux. Only
minimal changes (ns, ANOVA) in the level of radioactivity
were observed in noninjected (17+ 1, 68+ 34, 198+
100 DPM, n ¼ 9) oocytes and those injected with the chaperone
CD147 cRNA alone (40+ 17, 73+ 21, 157+ 57 DPM, n ¼
10). At time points 15 and 60, radioactivity in the medium of
oocytes injected with the transporter was significantly different
from the noninjected and chaperone only injected oocytes
(P, 0.0001, ANOVA) (Fig. 2B). Remaining radioactivity in
oocytes after the last time point was significantly reduced
(P, 0.0001) in coinjected (12 165+ 991 DPM) compared
with noninjected (34 418+ 951 DPM) andCD147only injected
oocytes (31 958+ 968 DPM, nNI ¼ 10, nCD147 ¼ 9, nCD147+
hMCT12 ¼ 8) (Supplementary Material, Fig. S2). These results
confirmed the data obtained from the metabolomics study and
demonstrated that the efflux of creatine depends on MCT12. In
an uptake experiment, we tested whether creatine transport is
bidirectional. In oocytes expressing MCT12, creatine uptake
was 195+ 12 pmol/h/oocyte compared with 1+ 0 pmol/h/
oocyte and 1+ 0 pmol/h/oocyte in the noninjected and CD147
only injected controls, respectively (n ¼ 10 for each group)
(Fig. 2C). The uptake of creatine was statistically significant
compared with controls (P , 0.0001, ANOVA, followed by
Tukey’s test). Therefore, we conclude that MCT12 transports
creatine into and out of a cell, probably depending on the creatine
concentration gradient. Uptake experiments using L-glutamine
as a substrate candidate did not yield MCT12 specificity (data
not shown).
Characterization of creatine transport by MCT12
To investigate whether the uptake was dependent on the sub-
strate concentration, different amounts of unlabeled creatine,
ranging between 1 and 3000 mM, together with a constant con-
centration of 14C creatine were used. The uptake profile followed
typical Michaelis–Menten kinetics (Fig. 3A) with a Vmax of
838.8 pmol/h/oocyte and a Km of 567.4 mM. This uptake is spe-
cific to MCT12 as only the presence of MCT12 supported creat-
ine uptake (P ≤ 0.0006, for every concentration tested, unpaired
t-test, n ¼ 7–10 per concentration and experimental group)
(Fig. 3A). Therefore, in the subsequent experiments, the values
of CD147 only injected oocytes are considered background
and will be subtracted from those obtained with MCT12. Crea-
tine uptake by MCT12 was not dependent on Na+ or Cl2 ions
(ND96: 180+ 13 pmol/h/oocyte, Na+ free: 169+ 8 pmol/h/
oocyte and Cl2 free: 174+ 16 pmol/h/oocyte, (n ¼ 19–25
oocytes per group, P ¼ 0.8002, ns, ANOVA) (Fig. 3B). Consi-
dering the pH (pH 7.4: 197+ 13 pmol/h/oocte; pH 5.5: 154+
11 pmol/h/oocyte, pH 6.5: 178+ 11 pmol/h/oocyte and pH
8.0 253+ 15 pmol/h/oocyte; n ¼ 26–33 per experimental
group), creatine uptake was slightly reduced under more acidic
conditions and significantly higher under more basic conditions
(P , 0.0001, ANOVA, pH 8 versus pH 7.4, P , 0.05; pH 8
versus pH 6.5, P, 0.001 and pH 8 versus pH 5.5, P , 0.001,
Tukey’s test) (Fig. 3C). We further tested whether creatine pre-
cursors (arginine, glycine and ornithine), creatine breakdown
product creatinine and the phosphorylated form of creatine
interfere with creatine transport by MCT12. None of the tested
compounds appeared to influence creatine uptake significantly
(P , 0.5358, ANOVA) (Experiment 1: creatine only: 225+
25 pmol/h/oocyte, arginine: 165+ 28 pmol/h/oocyte, glycine:
168+ 27 pmol/h/oocyte, ornithine: 164+ 34 pmol/h/oocyte
and phosphocreatine: 169+ 35 pmol/h/oocyte; (n ¼ 5–7); Ex-
periment 2: creatine only: 89+ 9 pmol/h/oocyte), creatinine
95+ 10 pmol/h/oocyte). To allow comparison of all com-
pounds, the results are displayed as percentage in Figure 3D.
SLC16A12mutation alters transport properties
In an SLC16A12 mutation screen of patients with age-related
cataracts (ARCs) we identified a novel heterozygous DNA
sequence alteration (Fig. 4A) that maps to position
c.1219G.A; p.G407S, affecting an evolutionary highly con-
served amino acid that localizes to the last extracellular loop.
This alteration was not found in 400 alleles from individuals
representing the general population. Potential development of
ARCs in this group is unlikely due to this sequence alteration.
The patient with the c.1219G.A alteration was diagnosed
Table 1. List of substrate candidates for MCT12 obtained from the metabolomic
analysis
Metabolite P-value two-way
ANOVA with
factors injection type
and medium
Log2 ratio
SLC16A12
injection over
control (CD147)
ADP-ribose 0.1240 3.8570
L-glutamine 0.0002 0.9945
O-Acetyl-L-homoserine 0.0441 0.8344
7-Methyluric acid 0.0239 0.7736
Dihydromacarpine 0.3990 0.7188
3-Amino-2-oxopropyl phosphate 0.415 0.7082
N-((R)-Pantothenoyl)-L-cysteine 0.0424 0.7034
L-2,3-Dihydrodipicolinate 0.0100 0.6902
Cobalt-precorrin 7 0.0900 0.6101
CDP choline 0.1982 0.5996
(-Dihydroorotate 0.0990 20.5854
1,4-Naphthoquinone 0.0990 20.5854
CDP 0.0967 20.6050
UDP glucuronate 0.3318 20.6058
Salicin 0.0054 20.6659
Benzo[a]pyrene-7,8-diol 0.0054 20.6659
Cellopentaose 0.2726 20.7048
5,6-Indolequinone-2-carboxylic
acid
0.0002 20.8816
3-Hydroxyanthranilate 8.93E205 20.9004
Creatine 3.11E207 22.6485
Statistical significance (two-way ANOVA) and fold change based on the
observed intensity (log2 ratio).
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with bilateral nuclear cataract with radial cortical opacities in
the left eye at the age of 69. To test whether this mutation
interferes with creatine transport, we generated a construct
of SLC16A12 that carries this mutation and performed crea-
tine uptake experiments as described above. Injection
of mutated cRNA into Xenopus laevis oocytes leads to
localization of MCT12 at the membrane (Fig. 1). Noticeably,
the uptake of creatine was significantly lowered by 43% (ref-
erence MCT12: 146+ 11 pmol/h/oocyte and mutant MCT12
p.G407S: 84+ 9 pmol/h/oocyte, P ¼ 0.0004, unpaired t-test)
(Fig. 4B). The mechanism based on which the mutation
alters creatine transport is not yet known.
Figure 2.Creatine is transported by MCT12. (A) Significantly lower creatine levels (6.3-fold) were detected in oocytes coinjected with SLC16A12 and its chaperone
CD147 compared with oocytes injected only with CD147. (B) Creatine efflux in noninjected oocytes (NI), and oocytes expressing CD147 or CD147 + hMCT12.
Content of 14C creatine in the medium was recorded as disintegrations per minute at different time points (0, 15 and 60 min). (C) Creatine uptake. Measurements
were taken 10 min after addition of 14C-creatine to the medium of oocytes (NI/CD147/CD147 + hMCT12). Uptake is shown as pmol/h/oocyte. Bars indicate SEM.
Figure3.Characterization of creatine uptake. (A) Michaelis–Menten kinetics of creatine uptake.Vmax ¼ 838.8 pmol/h/oocyte andKm ¼ 567.4 mM. (B) Ion depend-
ency of creatine uptake. Experiments were performed either in the presence of both sodium and chloride (NaCl) or in sodium (Na+) or chloride (Cl2)-free medium. (C)
pH dependency of creatine uptake. pH of 5.5, 6.5, 7.4 and 8.0 were tested. (D) Effect of potential competitors on creatine uptake. Creatine uptake alone (creatine) is
shown as 100%. Bars indicate SEM.
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In rats, Slc16a12 knockout (KO) animals did neither pheno-
copy the cataract nor the glucosuria phenotype (21), however
creatine levels in the urine were significantly elevated
(Fig. 4C). KO males accumulated 5.85 mM creatine compared
with 1.76 mM in age-matched heterozygous KO males, which
corresponds to an 3-fold difference. Likewise, an 2-fold
difference was measured in females with 2.12 mM creatine
in KO animals versus 1.01 mM in age-matched wild-type sib-
lings. These results suggest that loss of Slc16a12 results in the
retention of creatine in the urine and a single copy of the gene
is sufficient for creatine transport. Patients were not available
for urine analysis.
Relative expression of SLC16A12 and SLC6A8 displayed
tissue specificity
Expression of the two genes, SLC16A12 and SLC6A8, encod-
ing the creatine transporters, was investigated in various
human tissues (Fig. 4D). Experimental conditions were
chosen to allow assessment of the relative expression of the
two transcripts within a given tissue, not necessarily between
all tissues. In the lens, no striking difference was seen in the
relative expression of both the transporters. However, in the
kidney and retina, higher relative levels of SLC16A12 were
found. In brain, heart and muscle tissue, SLC6A8 was more
abundant. We concluded that tissue-specific differences in
gene expression exist, which are likely to reflect the respective
physiological functions.
DISCUSSION
The use of a metabolomics approach in combination with the
heterologous Xenopus laevis oocyte expression system resulted
in the identification of creatine as the substrate for the solute
carrier MCT12. This novel combination of technologies is a
powerful tool and our results open opportunities for substrate
identification of many of the remaining orphan transporters. Fur-
thermore, application of creatine may provide potential means of
prevention of ARCs.
Characteristics of the transporters
Until now, the only creatine transporter characterized is CRT1.
Here, we present the findings of a second creatine transporter
CRT2, known as MCT12. While the structural similarities of
both the transporters include the presence of 12 transmembrane
domains (25,27), their activity profile is quite distinct. In contrast
to MCT12, which performs facilitated transport of creatine,
likely along a concentration gradient, CRT1 requires sodium
and chloride ions and works against the creatine concentration
gradient (4,5,10). CRT1 is encoded bySLC6A8on the X chromo-
some (4,10) and mutations in SLC6A8 lead to mental retardation
often combined with speech delay and epileptic conditions, but
also with muscular dystrophy (10–12). The expression patterns
of the two creatine transporters are also distinct: the predominant
expression of CRT1 transcripts in the brain may correlate well
with the observed clinical symptoms of severe developmental
delays in patients with deficiencies in SLC6A8 (28,29). Among
the various deficiencies in patients with SLC6A8 mutations, cat-
aracts, microcornea or glucosuria were not reported. The latter
symptoms are seen in patients with mutations in SLC16A12
(25) but, in turn, these patients did not show obvious signs of de-
velopmental delay or other neurological disorders. Possibly, pre-
dominant expression of SLC16A12 compared with SLC6A8 in
kidney may help to explain this observation. Initial data on mem-
brane localization of the two creatine transporters indicate that
they occupy opposing sides of epithelial cells; MCT12 seems
predominantly at the basolateral membrane in lens (21), while
Figure 4. Effect of mutations on creatine transport and expression studies. (A) SLC16A12 mutation screen. Electropherograms of an unaffected individual and of a
patient with ARC showing the heterozygous mutation (arrow) SLC16A12 c.1219G.A, p.G407S. (B) 14C creatine uptake of oocytes expressing the mutant hMCT12
p.G407S compared with the reference hMCT12. The mutation causes a significant reduction in creatine uptake by 43% (P ¼ 0.0004). Uptake was recorded as pmol/h/
oocyte. Bars indicate SEM. (C) Creatine levels in urine of rats. Male Slc16a12KO or heterozygous (Het) rats and female KO and WT. Displayed are the percentages
relative to the unaffected (not KO) males and females at 100%. Bars indicate SEM. (D) Expression of creatine transporter transcripts in human tissues. RT–PCR using
primers specific for SLC16A12 (a) and SLC6A8 (b). Amplicon sizes are given in base pairs. Non-template control is water.
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CRT1 was found at the apical membrane in proximal tubule cell
lines and the proximal tubule in rats (8). A possible explanation
for transepithelial transport of creatine could be envisioned in
analogy to the paired transport system described for broad speci-
ficity, Na+-independent neutral and cation ionic amino acid
transporter (30). The absence of MCT12 but the presence of
CRT1 in the proximal convoluted tubule of the kidney of the
Slc16a12KO rat would help explain the observed increase spill-
age of creatine into the urine. It is not uncommon that mutations
in genes that are more generally expressed cause highly specific
clinical symptoms. Whether differences in function or expres-
sion or both are responsible for the activity of the two transpor-
ters need to await further experiments.
Proper maturation and localization of MCTs require chaper-
ones (22–24) and in HEK293 cells CD147 assumes this task
for MCT12 (21). In Xenopus laevis oocytes, the endogenous
level of the CD147 homolog (22) seems sufficient to properly
guide the transporter to the membrane. The proton environment
is known to affect transport activity and pH sensitivity known of
other members of the MCT family (31) also applies to MCT12,
such that creatine transport is significantly increased under basic
conditions. As MCT12 localizes to the lens cortex (21), these
findings correlate well with a pH gradient in the lens of a more
acidic core and a more basic cortex (32–34).
Aside from MCT12’s involvement in cataract, microcornea
and glucosuria, little is known on its function and biology. Re-
cently it was reported as a biomarker for prostate, colon and
breast cancers (35). A role of creatine in cancerous tissues is
not surprising, given that tumor growth is a high energy-
consuming process.
Function of the substrate creatine
Creatine is best known for its capacity as energy buffer via
phosphocreatine (PCr) (2). High levels of PCr are found in skel-
etal muscle, brain and retina (3) and its presence in the lens was
established by NMR studies (36), which implies a possible con-
tribution to the energy demand in this avascular structure. As dif-
ferentiated lens fiber cells mainly use glycolysis as an energy
source and do not have any direct oxygen supply from blood
vessels (37), an energy buffer such as creatine could be advanta-
geous. In this context, the cataract phenotype in patients with
mutations in SLC16A12 might be explained via altered proper-
ties of creatine transport leading to disturbance of energy metab-
olism and resulting in structural changes and opacities within the
lens. The relatively high level of PCr in human lens compared
with other mammals (36) may indicate species-specific variation
in its function, which may have contributed to the lack of catar-
acts in Slc16a12 KO rats (21).
Furthermore, creatine was found to have antioxidative func-
tion (38), which could be beneficial to the aging cell. It could
act as a mild antioxidant in the lens, which is exposed to environ-
mental and molecular factors of oxidative stress (i.e. glutathi-
one) (39). The fact that age-related processes like ARC are
affected by MCT12 (40) supports this point. In addition, creatine
also functions as cytoprotective, anti-apoptotic reagent (41,42).
In the lens, an attenuated apoptotic-like process leads to loss of
organelles as part of the differentiating process (43) and creatine
might play a role in this attenuated process.
Within the kidney, the involvement of creatine in glucosuria
could be envisioned with focus on the action of the Na+-K+-
ATPase. It generates a sodium gradient, which is required for
glucose reabsorption in the kidney proximal tubule performed
by secondary activity of the sodium-glucose linked transporters
SGLT1 and 2 (44). As PCr is able to support maximal pump
function of the Na+-K+-ATPase in kidney cells (45), a possible
hypothesis is that disturbance of creatine transport could
lead to inefficient glucose reabsorption. Alternatively, at a
cellular level, renal glucosuria could be a response to ER
stress, followed by the unfolded protein response, as this
pathway was recently suggested to influence central metabolic
processes, particularly glucose metabolism (46). In support is
our previously reported finding that the SLC16A12 premature
termination mutation in patients with renal glucosuria (25)
elicits UPR in cell culture (21).
Taken together, the here reported findings will further our
understanding of creatine homeostasis and the role of both trans-
porters during this process. Upon further investigations, creatine
may become a preventive supplement for the most prevalent
age-related vision impairment, cataracts.
MATERIALS AND METHODS
Cloning
The following constructs were generated for the purpose of expres-
sion in the heterologousXenopus laevis oocyte system. All restric-
tion enzymes were purchased from Fermentas (St. Leon-Rot, DE),
unless otherwise stated. As vector we used the BlueScript derived
vector KSM (provided by Leila Virkki). The correct DNA se-
quence of all cloned inserts was verified by Sanger sequencing.
For human reference SLC16A12 (ENST00000341233; protein
Q6ZSM3) a partial sequence in EST clone IRAKp961C20200Q
(imaGenes) was completed using complementary DNA (cDNA)
gained from HEK293 cells. Isolated RNA (RNeasy Kit; Qiagen)
was treated with DNase and reverse transcribed using random
hexamers for priming and SuperScript III (Invitrogen). An RT–
PCR with a template mixture of clone IRAKp961C20200Q and
cDNA, primers SLC16A12_CL1_for and CL2.2_rev (Supple-
mentary Material, Table S1) and Pfu DNA polymerase
(Promega) were incubated (958C 2 min; 948C 1 min; 558C 30 s;
728C 4 min; ×40; 728C 5 min). Human mutation SLC16A12
(c.1219G.A) was generated by site-directed mutagenesis with
the reference clone as a template and primers SLC16A12_CL1_
for, MCT12_1219A_long_f, MCT12_1219T_long_r and
SLC16A12_CL2.2_rev, specific for the sequence alteration (Sup-
plementary Material, Table S1) and cloned into KSM. The mouse
CD147-pOTB7 cDNA was acquired from IMAGE consortium
(3589236) and subcloned with SalI/NotI into the pCMV-sport6
expression vector.
In vitro transcription
KSM clones were linearized with SacII. CD147-pCMV-sport6
was linearized with NheI. In vitro transcription was performed
using the respective MEGAscriptw kit (Ambion).
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Xenopus laevis ooctes and injections
Oocytes were surgically removed from Xenopus laevis and
treated as described (20). For injection, a Nanoject II microinjec-
tor (Drummond) was used. A minimum of five oocytes were
injected for each experimental condition. Injection volume
was 50 nl. The amount of cRNA was 10 ng for CD147 and
20 ng for the transporter. Oocytes were kept at 188C in ND96
medium supplemented with 5 mg/l doxycycline and gentamy-
cin, each. For efflux, 100 mM creatine supplemented with
10 nCi of 14C radiolabeled creatine (Hartmann Analytic) was
injected 3 days after cRNA injection. Oocytes were incubated
at 258C in ND96 (please refer Supplementary Material,
Table S1, for medium compositions). Medium aliquots
were removed and radioactivity was measured using
Emulsifier-SafeTM scintillation cocktail (PerkinElmer) and a
Tri-Carb 2900TR Liquid Scintillation Analyzer (Packard).
Efflux was stopped by washing the oocytes with ND96.
Oocytes were lysed with sodium dodecyl sulphate (SDS) and
radioactivity was measured. For uptake, 3 days after injection,
oocytes were washed with ND96 and incubated at 258C for 2
min. ND96 was replaced with 100 mM uptake solution (concen-
trations ranging from 1 to 3000 mM were used for Michaelis–
Menten kinetics), supplemented with 0.2 mCi 14C-radiolabeled
creatine. After 10 min, uptake was stopped by removing the
uptake solution followed by washing the oocytes with ND96.
The oocytes were further processed as described for the efflux
experiments and radioactivity measured. For competition
uptake experiments, in addition to creatine, 1 mM of arginine,
glycine, ornithine, phosophocreatine and creatinine was added.
For ion- and pH dependency experiments, modified ND96
media supplemented with creatine were used (Supplementary
Material, Table S2). Results from all efflux and uptake experi-
ments were statistically analyzed and plotted using Prism
software (http://www.graphpad.com/scientific-software/prism/,
last date accessed on 15 April 2013). Unpaired tests or
Michaelis–Menten kinetics were applied. Confidence intervals
were calculated and included in the graphs.
Cryosectioning
Three days after injection of cRNA, oocytes were washed in
phosphate buffered saline (PBS) (Gibco) and fixed for 2 h in
4% paraformaldehyde at 48C and incubated at 48C in 30%
sucrose overnight. Three to five oocytes were placed in a 10 ×
10 × 5 mm Tissue-Tekw Cryomoldw (Sakura Finetek) filled
with Tissue-Tekw (Sekura Finetek) and 7 mm sections were
cut using a CM3050 S cryostat (Leica). Sections were placed
on SuperFrostw slides and stored overnight at 2208C.
Immunofluorescence
Cryosections were blocked for 1 h [PBS containing 0.05%
Tween (PBST) and 1% BSA (Sigma)]. Antibodies against the
C-terminal end of human MCT12 (21) (dilution 1:500) and the
Bandeiraea simplicifolia isolectin B4 FITC conjugate
(IB4-FITC, Sigma) (dilution 1:100) were applied and the
slides incubated overnight at 48C. Samples treated with
IB4-FITC were mounted using Fluoromount (Sigma) and cover-
slips (44). Samples treated with the MCT12 antibody were
incubated with secondary goat anti-rabbit IgG Alexa Fluorw
488 (Invitrogen) (1:200 dilution) (60 min) and mounted.
Samples treated with the secondary antibody only were included
as control. Pictures were recorded on an Axioplan 2 imaging
system (Zeiss) with an Axiocam MRm camera (Zeiss) and
processed with Photoshop CS4 (Adobe).
Transcript analysis
RNA of human tissues was obtained from Takara Bio Europe/
Clontech (Saint-Germain-en-Laye, France). Reverse transcrip-
tion was performed using Superscript III (Invitrogen). RT–
PCR was carried out using an annealing temperature of 608C
and 32 cycles for SLC6A8 (primer pair SLC6A8 hum ex6up
and SLC6A8 hum ex5dn amplifying a fragment of 150 bp) and
SLC16A12 (primer pair SLC16A12 RNA 4/5f and SLC16A8
RNA 6r). Lens RNA from a donor eye was 3 fold concentrated
using the concentrator 5301 from Eppendorf prior to reverse
transcription treatment. Resulting cDNA required 41 cycles in
RT–PCR (25).
Creatine assay
Urine was collected from wild-type (3 female), Slc16a12+/2
(3 male) and Slc16a122/2 (3 female and 3 male) rats, then cen-
trifuged at 3000g for 10 min to remove any particulate matter.
Supernatants were taken and stored at2808C. The levels of cre-
atine in the urine of wild-type, heterozygous and homozygous
Slc16a12male and female rats were measured using the creatine
assay kit from BioVision.
Metabolomics
Sample preparation and handling
Oocytes were coinjected with SLC16A12 plus CD147 or with
CD147 alone and incubated for 2 days. At this point, 20
oocytes per condition were incubated for additional 2 days in
either ND96 or rich medium (Supplementary Material,
Table S3), which was supplemented with metabolites mimick-
ing human plasma (47,48) and Kao and Michayluk vitamin
mix (Sigma) (49). Oocytes were lysed in ND96 supplemented
with protease inhibitors (Sigma). Samples were centrifuged
(48C; 25 000 rcf; 5 min). The supernatant was subjected to
repeated (2×) centrifugation and concentrated to a final
volume of 100 ml. For LC-MS analysis, three aliquots of 20 ml
of the oocyte lysates were diluted (1:5) with 50 mM ammonium
acetate in acetonitrile/methanol/water/saturated aqueous am-
monium hydroxide (900:90:9:1,v/v, pH 9). All reagents, refer-
ence compounds and internal standards were purchased from
Sigma-Aldrich Fluka (Buchs, Switzerland). LiChrosolv grade
organic solvents for LC and sample dilution were obtained
from Merck (Darmstadt, Germany) and HPLC grade water
was obtained from Sigma-Aldrich (Steinheim, Germany).
Hydrophilic interaction chromatography was performed on a
nano-UPLC system (Waters Inc. Milford, USA). Mobile phase
A was 0.5 mM ammonium acetate in water/saturated aqueous am-
monium hydroxide (998:2,v/v, pH 9) and mobile phase B was
0.5 mM ammonium acetate in acetonitrile/water/saturated
aqueous ammonium hydroxide (950:48:2,v/v, pH 9). A solvent
gradient starting from 10%A at initial run time to 50%A at
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10 min run time was applied. The initial flow rate of 6 ml/min was
lowered to 4 ml/min at 10 min run time. The run was completed by
a washing phase of 4 min at 10%A. Selfmade spray tip columns of
150 × 0.2 mm, packed with Waters BEH Amide type solid phase
(1.7 mm average particle size), were used.
The UPLC system was coupled by a nano-ESI source to a
Synapt G2 HDMS (Waters, Manchester, UK). Negative mode
MSE data over a mass range of 50–1200 m/z were acquired
with a rate of 3 spectra/sec for the entire UPLC run. Leucine en-
kephalin (2 ng/mL in acetonitrile/water 50:50 v/v with 0.1%
formic acid v/v) was used as internal lock mass.
Data processing and data analysis
Centroided MS data (function 1 of the acquired MSE data) were
processed by MarkerLynx XS 4.1 (Waters, Manchester, UK)
to obtain a primary list of [M-H]2 ions detected in any of the
samples, together with its intensity in all samples. This
primary list was searched in a database with a mass tolerance
of 50 mDa and with the assumption that all metabolites only
form [M–H]2 ions. A custom MarkerLynx database containing
3166 exact mass values, metabolite IDs, molecular formulas and
pathway information of all KEGG listed metabolites (http://
www.genome.jp/kegg/) was queried. The resulting annotated
spectral intensity data matrix of the form n detected masses ×
p samples was imported in an R workspace (www.r-project.
org, last accessed on 15 April 2013) to perform descriptive sta-
tistics, univariate and multivariate data analyses. BGA based
on correspondence analysis (CoA) was used to detect and visu-
alize metabolites affected by the experimental conditions, i.e.
potentially transported across the oocyte membrane (R library
made4, (50)). The intensity data for the top candidates detected
by BGA were additionally analyzed by one-way as well as
two-way ANOVA (as appropriate) and visualized by boxplots.
SLC16A12 mutation screen
Patients with ARCs were seen by an ophthalmologist (FM) and
they gave informed consent. The study conformed to the stan-
dards set by the Declaration of Helsinki, Conditions for the
DNA mutation screen have been described (40). Control indivi-
duals represent the general population; they were not age-
matched and may develop ARC.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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